Search
Research
Secondary Antibiotic Prophylaxis for Latent Rheumatic Heart DiseaseRheumatic heart disease affects more than 40.5 million people worldwide and results in 306,000 deaths annually. Echocardiographic screening detects rheumatic heart disease at an early, latent stage. Whether secondary antibiotic prophylaxis is effective in preventing progression of latent rheumatic heart disease is unknown.
Research
A population pharmacokinetic study of benzathine benzylpenicillin G administration in children and adolescents with rheumatic heart diseaseFew children and adolescents receiving BPG as secondary prophylaxis will achieve concentrations >0.02 mg/L for the majority of the time between injections
Research
Immuno-nephelometric determination of group streptococcal anti-streptolysin O titres (ASOT) from dried blood spots: Method for validating a new assayThis study was designed to determine the sensitivity and reproducibility of recovering anti-streptolysin O titres (ASOT) from dried blood spot (DBS) samples
Research
Clinical development strategy for a candidate group A streptococcal vaccineThis review outlines a clinical development strategy detailing the phases of development required for registration of a candidate Group A streptococci vaccin
Research
Long-term outcomes from acute rheumatic fever and rheumatic heart disease: A Data-Linkage and Survival Analysis ApproachAdverse outcomes for people with acute rheumatic fever and rheumatic heart disease and the effect of comorbidities and demographic factors on these outcomes
Research
Availability and administration of benzathine penicillin G for the prevention of rheumatic fever in Africa: Report of the Working Group on PenicillinBenzathine penicillin G availability should be addressed and African health workers’ knowledge and practices need to be augmented
Research
Rheumatic heart disease in Indigenous children in northern Australia: Differences in prevalence and the challenges of screeningThis study compared regional differences in the prevalence of rheumatic heart disease in Indigenous Australian children, and describes the logistical and...
Research
Supply of benzathine penicillin G: the 20-year experience in AustraliaReliable supplies of BPG are essential for delivering the recommended schedule of secondary prophylaxis for people living with RHD.
Research
Rheumatic heart disease across the Western Pacific: not just a Pacific Island problemWe aimed to review RHD burden in Western Pacific Region outside Oceania to identify countries with high RHD burden
Research
Quality of benzathine penicillin G: A multinational cross-sectional studyBenzathine penicillin G (BPG) is used as first-line treatment for most forms of syphilis and as secondary prophylaxis against rheumatic heart disease (RHD). Perceptions that poor quality of BPG is linked to reported adverse effects and therapeutic failure may impact syphilis and RHD control programs. Clinical networks and web-based advertising were used to obtain vials of BPG from a wide range of countries.